Discovering targeted
medicines

Redx is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted medicines for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis

Targeting fibrosis

Redx is a clinical-stage biotechnology company focused on the development of novel, small molecule, targeted medicines for the treatment of fibrotic disease. ​

Our core strengths in medicinal chemistry and translational science have enabled us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets where there is an opportunity to create best-in-class or first-in-class treatments for diseases of unmet medical need. We have built an attractive portfolio of assets and have a strong track record of drug discovery having delivered six molecules to clinical stage development. ​

​Our strategic focus is on advancing our differentiated lead asset, RXC008, a potential first-in-class GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease and building our programme targeting DDR, a novel fibrosis target. ​

GI-restricted pan-ROCK Inhibitor
(RXC008)

GI-restricted pan-ROCK Inhibitor
(RXC008)

RXC008 is a clinical stage, orally active GI-restricted pan-ROCK (ROCK1/2) inhibitor being developed for the treatment of fibrostenotic Crohn’s disease.

DDR - Discoidin
Domain Receptor
inhibition ​

DDR - Discoidin
Domain Receptor
inhibition ​

Potential first-in-class DDR inhibitor programme for chronic kidney disease.

We have earmarked key programmes in our pipeline for partnership including zelasudil (RXC007), a next-generation, selective ROCK2 inhibitor for the treatment of interstitial lung diseases and multiple fibrotic diseases and zamaporvint (RXC004), a clinical stage Porcupine inhibitor targeting Wnt-ligand dependent tumours, in combination with anti-PD-1 therapy. ​

ROCK2 Selective Inhibitor
Zelasudil (RXC007)

ROCK2 Selective Inhibitor
Zelasudil (RXC007)

Zelasudil is a clinical stage, highly selective and orally available ROCK2 inhibitor being developed for the treatment of interstitial lung diseases and other fibrotic indications.

Porcupine Inhibitor
Zamaporvint (RXC004)

Porcupine Inhibitor
Zamaporvint (RXC004)

Zamaporvint is a clinical stage, highly potent and selective, orally active once-daily Porcupine inhibitor being developed as a targeted therapy for Wnt-ligand driven cancer.

Our values

At Redx, our ambition is to create world leading medicines that will transform patients’ lives, by delivering better medicines faster.

Our core strengths in medicinal chemistry and translational science enable us to discover and develop potentially differentiated, novel compounds against biologically or clinically validated targets where there is the opportunity to create best-in-class or first-in-class treatments for diseases of unmet medical need.

Our five core company values that underpin everything we do: